This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (20) Citing Articles via Google Scholar Google Scholar Articles by Finn, A. V. Articles by Gold, H. K. Search for Related Content PubMed PubMed Citation Articles by Finn, A. V. Articles by Gold, H. K.

Drug-eluting stents for diabetes mellitus

A rush to judgment?

Aloke V. Finn, MD^*,*, Igor F. Palacios, MD^*, Adnan Kastrati, MD and Herman K. Gold, MD^*

^* Cardiac Unit, Massachusetts General Hospital, Boston, Massachusetts
Deutsches Herzzentrum and 1. Med. Klinik rechts der Isar, Technische Universität München, Munich, Germany

View larger version (14K): [in a new window]   Figure 1 Comparison of rates of angiographic restenosis and target lesion revascularization (TLR) for diabetic patients enrolled in the Sirolimus-coated BX Velocity Balloon-Expandable Stent in the treatment of Patients with De Novo Coronary Artery Lesions (SIRIUS) (1), Polymer-Based Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease (TAXUS-IV) (2), and Intracoronary Stenting and Angiographic Results (ISAR-STEREO) (12,13) trials (95% confidence intervals [CI] are illustrated).